SAN DIEGO, Calif., Sept. 8, 2011 /PRNewswire/ --HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China's novel Traditional Chinese Medicines (TCM).
The partnership is expected to bring productive synergy between the two parties. Zhejiang Chinese Medical University Life Science College, a prominent traditional Chinese medicine university in southern China, is recognized for its strength in leading-edge research in TCM. HUYA has a strong commitment toward developing novel therapeutics from TCM in areas of unmet medical needs. HBI-3000, HUYA's novel anti-arrhythmic compound currently in development in both China and the U.S., was originally derived from a TCM.
HUYA is one of the first companies to have recognized China's potential to help meet the global need for new preclinical and clinical stage compounds. The company is committed to facilitating and promoting the global development and commercialization of novel pharmaceutical products originating in China. HUYA has established a series of collaborations with leading universities and research institutions throughout China and has pioneered in-licensing innovative compounds from the country, utilizing its expertise to advance these compounds for global markets.
"The alliance with Zhejiang Chinese Medical University Life Science College will further strengthen HUYA's collaborative efforts with the faculty and researchers of the university," said Clement Gingras, HUYA's CTO and COO, China. "Together, HUYA and Zhejiang Chinese Medical University Life Science College will help advance the progression of TCM to the global markets, benefiting patients worldwide."
Dr. Zhishan Ding, Associate Dean of Zhejiang Chinese Medical University Life Science College, commented, "Our College is dedicated to promoting TCM innovations. We are delighted to collaborate with HUYA and together we will share the commitment towards the global development of novel therapeutics from TCM in areas of unmet medical need."
ABOUT HUYA BIOSCIENCE INTERNATIONAL
HUYA is the leader in global pharmaceutical co-development with Chinese partners. With seven offices strategically located in China, the most comprehensive Chinese compound portfolio, and a rapidly growing number of exclusive agreements with premier Chinese research and development organizations, HUYA is uniquely positioned to identify and license novel Chinese compounds. HUYA offers Western pharmaceutical companies efficient access to innovative therapeutic opportunities and helps to reduce deal-making complexity in China. The company has become a champion of guiding China's biomedical innovations to the worldwide marketplace. HUYA has joint headquarter offices in San Diego, CA, USA and Shanghai, China. Additional information about the company is available at www.huyabio.com
ABOUT ZHEJIANG TCM UNIVERSITY LIFE SCIENCE COLLEGE
Zhejiang Chinese Medical University Life Science College, established in April 2000, is a successor of the Institute of Molecular Medicine. The college has six research departments: Biochemistry, Genetics and Molecular Biology, Cell Biology, Microbiology and Immunology, General Biology, and Clinical Laboratory Science. With well-defined missions, elite faculty, and outstanding educational subjects, Zhejiang Chinese Medical University Life Science College is now a leading institute for TCM in China. It has received various awards, developed two new drugs (one successfully marketed), undertaken a significant number of projects, and published numerous papers. For more information, please visit http://sk.zjtcm.net/
Yung-Chih Wang, Ph.D., MBA
Vice President, Corporate Development, China
HUYA Bioscience International
Qing (Vicky) Xia, MS, MBA
Senior Business Development Manager
HUYA Bioscience International
SOURCE HUYA Bioscience International